Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-β gene therapy

Melanoma Research

Volumn 13, Issue 4, 2003, Pages 349-356

  Ryuke, Yasushi ^a   Mizuno, Masaaki ^a   Natsume, Atsushi ^a   Suzuki, Osamu ^a   Nobayashi, Misato ^a   Kageshita, Toshiro ^b   Matsumoto, Kazuhiko ^c   Saida, Toshiaki ^c   Yoshida, Jun ^a,d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NONE   (Japan)

Author keywords

Apoptosis; Gene therapy; Interferon ; Liposome; Melanoma; Natural killer cells

Indexed keywords

BETA INTERFERON; LIPOSOME;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GROWTH INHIBITION; IMMUNOCYTOCHEMISTRY; MELANOMA; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CATIONS; CELL DIVISION; CELLS, CULTURED; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; INTERFERON-BETA; KILLER CELLS, NATURAL; LIPOSOMES; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS; TRANSFECTION;

EID: 0042367522     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200308000-00003     Document Type: Article

References (33)

1. Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 1997; 17:355-367.
2. Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS, et al. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res 2000; 6:3354-3360.
3. Sanceau J, Hiscott J, Delattre O, Wietzerbin J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 2000; 19:3372-3383.
4. Zhang H, Koty PP, Mayotte J, Levitt ML. Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines. Exp Cell Res 1999; 247:133-141.
5. Duncan GS, Mittrucker HW, Kagi D, Matsuyama T, Mak TW. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med 1996; 184:2043-2048.
6. Allavena P, Giardina G, Sen S, Colella G, Broggini M, D'Incalci M. IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents. J Interferon Cytokine Res 1998; 18:87-93.
7. Vilcek J, De Maeyer E. Interferons and the Immune System. Amsterdam: Elsevier Press; 1984.
8. Friedman RM. Interferons. In: Oppenheim JJ, Shevach EM (editors): Textbook of Immunophysiology. New York: Oxford University Press; 1988, pp. 94.
9. Ortaldo JR, Herberman RB. Augumentation of natural killer activity. In: Lotzova E, Herberman RB (editors): Immunobiology of Natural Killer Cells, vol. 2. Boca Raton: CRC Press; 1986, pp. 145.
10. Boraschi D, Soldateschi D, Tagliabue A. Macrophage activation by interferon: dissociation between tumoricidal capacity and suppressive activity. Eur J Immunol 1982; 12:320-326.
11. Crawford RM, Leiby DA, Green SJ, Nacy CA, Fortier AH, Meltzer MS. Macrophage activation: a riddle of immunological resistance. Immunol Ser 1994; 60:29-46.
12. Belardelli F, Ferrantini M, Santini SM, Baccarini S, Proietti E, Colombo MP, et al. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Cancer Res 1998; 58:5795-5802.
13. Pilling D, Akbar AN, Girdlestone J, Orteu OH, Borthwick NJ, Amft N, et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol 1999; 29:1041-1050.
14. von Hoegen P. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett 1995; 47:157-162.
15. Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 2000; 156:1381-1393.
16. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, et al. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 1999; 59:872-879.
17. Einhorn S, Strander H. Interferon treatment of human malignancies - a short review. Med Oncol Tumor Pharmacother 1993; 10:25-29.
18. Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 1996; 16:275-281.
19. Harada K, Yoshida J, Mizuno M, Kurisu K, Uozumi T. Growth inhibition of intracerebral rat glioma by transfection-induced human interferon-beta. J Surg Oncol 1995; 59:105-109.
20. Mizuno M, Yoshida J, Sugita K, Inoue I, See H, Hayashi Y, et al. Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res 1990; 50:7826-7829.
21. Yoshida J, Mizuno M, Yagi K. Cytotoxicity of human beta-interferon produced in human glioma cells transfected with its gene by means of liposomes. Biochem Int 1992; 28:1055-1061.
22. Mizuno M, Yoshida J. Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Cancer Immunol Immunother 1998; 47:227-232.
23. Natsume A, Mizuno M, Ryuke Y, Yoshida J. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 1999; 6:1626-1633.
24. Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J. IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 2000; 47:117-124.
25. Colamonici OR, Domanski P, Platanias LC, Diaz MO. Correlation between interferon (IFN) alpha resistance and deletion of the IFN alpha/beta genes in acute leukemia cell lines suggests selection against the IFN system. Blood 1992; 80:744-749.
26. Coleman A, Fountain JW, Nobori T, Olopade OI, Robertson G, Housman DE, Lugo TG. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res 1994; 54:344-348.
27. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992; 89:10557-10561.
28. Heyman M, Grander D, Brondum-Nielsen K, Liu Y, Soderhall S, Einhorn S. Deletions of the short arm of chromosome 9, including the interferon-alpha/-beta genes, in acute lymphocytic leukemia. Studies on loss of heterozygosity, parental origin of deleted genes and prognosis. Int J Cancer 1993; 54:748-753.
29. James CD, He J, Carlbom E, Nordenskjold M, Cavenee WK, Collins VP. Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res 1991; 51:1684-1688.
30. Hanson C, Kopf I, Weijdegar B, Weimarck A, Stierner U. Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines. Melanoma Res 1999; 9:451-456.
31. Wells V, Mallucci L. Cell cycle regulation (G1) by autocrine interferon and dissociation between autocrine interferon and 2′,5′-oligoadenylate synthetase expression. J Interferon Res 1988; 8:793-802.
32. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 1996; 16:759-764.
33. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 2000; 20:857-866.